Breaking News Instant updates and real-time market news.

CELG

Celgene

$83.86

1.42 (1.72%)

07:35
07/10/18
07/10
07:35
07/10/18
07:35

Celgene announces IMpassion130 study meets co-primary endpoint of PFS

Celgene announced that the Phase III IMpassion130 study met its co-primary endpoint of progression-free survival, or PFS. This is the first phase III study to demonstrate a statistically significant PFS improvement in first-line metastatic or unresectable locally advanced triple negative breast cancer, or TNBC, a type of breast cancer with high unmet need. Results demonstrated that the investigational combination of Tecentriq plus Abraxane compared to Abraxane monotherapy, as an initial treatment, significantly reduced the risk of disease worsening or death in patients with metastatic or unresectable locally advanced TNBC in the intention-to-treat and PD-L1 positive populations. Overall survival is encouraging in the PD-L1 positive population at this interim analysis, and follow up will continue until the next planned analysis. Safety in the Tecentriq plus Abraxane arm appeared consistent with the known safety profiles of the individual medicines, and no new safety signals were identified with the combination.

  • 26

    Jul

CELG Celgene
$83.86

1.42 (1.72%)

07/10/18
PIPR
07/10/18
DOWNGRADE
Target $52
PIPR
Neutral
Acceleron downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff downgraded Acceleron Pharma (XLRN) to Neutral and lowered his price target for the shares to $52 from $55. Acceleron and partner Celgene (CELG) last night announced positive Phase III Believe results for luspatercept in transfusion dependent beta thalassemia, Tenthoff tells investors in a research note. The stock in premarket trading is up $6.10, or 13%, to $53.50. This is a nice second win for luspatercept, but Acceleron shares are not a buy at current valuation levels, the analyst contends. He believes luspatercept does not command the same market opportunity in beta thalassemia due to the expected approval of curative gene therapy by 2020. As such, Tenthoff lowered his penetration rates for luspatercept in beta thal to account for gene therapy competition. He says, however, that partner Celgene could acquire Acceleron, which presents a risk to his downgrade.
07/06/18
MSCO
07/06/18
NO CHANGE
MSCO
Morgan Stanley doesn't expect much movement in Celgene on settlement news
Morgan Stanley analyst Matthew Harrison noted that Celgene announced a settlement of ongoing Revlimid patent litigation with Accord Healthcare in the U.K., though he does not expect the stock to move much on this development given that most investors anticipated a generic version of the drug arriving in the EU by the early 2020s. Additionally, he believes investors are more heavily focused on Revlimid's intellectual property situation in the U.S. Harrison maintains his Equal Weight rating and $90 price target on Celgene shares.
06/29/18
JEFF
06/29/18
NO CHANGE
Target $115
JEFF
Buy
Luspatercep data could turn around negative Celgene sentiment, says Jefferies
Last night's positive Phase III data for luspatercep represents a $1B-$2B opportunity and could help turn around negative sentiment on Celgene, Jefferies analyst Michael Yee tells investors in a research note titled "Some Good News Helps Re-instill Some Confidence in Pipeline." The stock is "cheap and assumes nearly no pipeline at current levels," Yee contends. He sees "numerous key catalysts" in the second half of 2018 and keeps a Buy rating on Celgene with a $115 price target.
06/28/18
PIPR
06/28/18
NO CHANGE
Target $55
PIPR
Overweight
Acceleron price target raised to $55 at Piper Jaffray after luspatercept data
Piper Jaffray analyst Edward Tenthoff raised his price target on Acceleron (XLRN) to $55 and kept his Overweight rating after the company's Phase 3 MEDALIST trial of luspatercept in myelodysplastic syndromes - MDS - met the primary and secondary endpoints. The analyst notes that the company, along with its partner Celgene (CELG) will now report full data at a medical conference this year and then file an NDA and MAA in the first half of next year. Tenthoff adds that today's results increase his confidence for luspatercept in lower-risk, front-line MDS.

TODAY'S FREE FLY STORIES

CVS

CVS Health

$73.76

-0.73 (-0.98%)

11:25
10/15/18
10/15
11:25
10/15/18
11:25
Conference/Events
Economic Club of Washington, D.C. to hold luncheon meeting »

Luncheon Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

S

Sprint

$6.35

-0.04 (-0.63%)

11:20
10/15/18
10/15
11:20
10/15/18
11:20
Options
Size ratio spread in Sprint »

Size ratio spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 13

    Nov

11:20
10/15/18
10/15
11:20
10/15/18
11:20
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
10/15/18
10/15
11:17
10/15/18
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBAN

Huntington Bancshares

$14.29

-0.08 (-0.56%)

11:17
10/15/18
10/15
11:17
10/15/18
11:17
Technical Analysis
Technical Take: Huntington Bancshares breaks support »

The shares are down 0.7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

PAR

PAR Technology

$20.31

-0.69 (-3.29%)

11:16
10/15/18
10/15
11:16
10/15/18
11:16
Hot Stocks
Voss Capital supports ADW's call for PAR Technology board to pursue alternatives »

Voss Capital, LLC, which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
10/15/18
10/15
11:16
10/15/18
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$59.01

-0.67 (-1.12%)

11:15
10/15/18
10/15
11:15
10/15/18
11:15
Options
Weibo put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
10/15/18
10/15
11:15
10/15/18
11:15
General news
Breaking General news story  »

3-Month Bill Auction to…

11:15
10/15/18
10/15
11:15
10/15/18
11:15
General news
Breaking General news story  »

6-Month Bill Auction to…

11:13
10/15/18
10/15
11:13
10/15/18
11:13
Hot Stocks
Breaking Hot Stocks news story  »

Bio Rad Laboratories…

11:10
10/15/18
10/15
11:10
10/15/18
11:10
General news
Treasury announced a $25 B 8-week bill for the inaugural sale Tuesday »

Treasury announced a $25…

TXT

Textron

$65.88

0.81 (1.24%)

11:06
10/15/18
10/15
11:06
10/15/18
11:06
Hot Stocks
TRU Simulation + Training, FlightSafety International enter LOI to form JV »

TRU Simulation +…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

11:05
10/15/18
10/15
11:05
10/15/18
11:05
Hot Stocks
Breaking Hot Stocks news story  »

Bio Rad Laboratories…

11:05
10/15/18
10/15
11:05
10/15/18
11:05
General news
Today's U.S. reports »

Today's U.S. reports…

MANU

Manchester United

$21.87

0.59 (2.77%)

11:03
10/15/18
10/15
11:03
10/15/18
11:03
Periodicals
Manchester United target for possible takeover by Saudi prince, The Sun says »

Saudi Crown Prince…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTAP

NetApp

$75.53

-1.43 (-1.86%)

, EQIX

Equinix

$399.68

3.96 (1.00%)

11:03
10/15/18
10/15
11:03
10/15/18
11:03
Hot Stocks
NetApp appoints Debra McCowan as chief human resources officer »

NetApp (NTAP) announced…

NTAP

NetApp

$75.53

-1.43 (-1.86%)

EQIX

Equinix

$399.68

3.96 (1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 24

    Oct

  • 25

    Oct

  • 01

    Nov

  • 07

    Nov

  • 07

    Nov

  • 10

    Dec

SMH

Market Vectors Semiconductor

$96.42

-0.92 (-0.95%)

11:03
10/15/18
10/15
11:03
10/15/18
11:03
Technical Analysis
Technical Take: Market Vectors Semiconductor breaks support, nears 52-week lows »

The Market Vectors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMB

iShares JP Morgan USD Emerging Markets Bond ETF

$105.88

0.04 (0.04%)

11:00
10/15/18
10/15
11:00
10/15/18
11:00
Options
Position adjustment in Emerging Markets bond ETF »

Position adjustment in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDXG

MiMedx

$5.25

0.11 (2.14%)

10:58
10/15/18
10/15
10:58
10/15/18
10:58
Hot Stocks
Viceroy: MiMedx's appointment of Alvarez, Marsal 'conflict of interest' »

In an open letter to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

ATVI

Activision Blizzard

$74.92

-3.07 (-3.94%)

, MCD

McDonald's

$164.56

0.74 (0.45%)

10:57
10/15/18
10/15
10:57
10/15/18
10:57
Recommendations
Fly Intel: Today's top analyst calls on Wall Street »

Check out today's…

ATVI

Activision Blizzard

$74.92

-3.07 (-3.94%)

MCD

McDonald's

$164.56

0.74 (0.45%)

TPR

Tapestry

$42.89

-0.92 (-2.10%)

LULU

Lululemon

$143.24

-0.46 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 23

    Oct

  • 19

    Nov

10:55
10/15/18
10/15
10:55
10/15/18
10:55
Conference/Events
Wedbush restaurants analyst to hold a luncheon »

Restaurants Analyst…

WPC

W.P. Carey

$63.80

0.61 (0.97%)

, GPN

Global Payments

$115.68

-1.72 (-1.47%)

10:54
10/15/18
10/15
10:54
10/15/18
10:54
Conference/Events
Wedbush IT services & payments analyst to hold dinner meeting »

In conjunction with the…

WPC

W.P. Carey

$63.80

0.61 (0.97%)

GPN

Global Payments

$115.68

-1.72 (-1.47%)

FDC

First Data

$23.21

0.02 (0.09%)

TSS

TSYS

$92.71

-1.235 (-1.31%)

SQ

Square

$73.51

-0.455 (-0.62%)

PYPL

PayPal

$77.74

-1.28 (-1.62%)

MA

MasterCard

$200.90

-3.06 (-1.50%)

V

Visa

$138.45

-1.57 (-1.12%)

ADS

Alliance Data

$211.66

-2.09 (-0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 21

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 13

    Nov

  • 26

    Nov

  • 03

    Mar

UNFI

United Natural Foods

$26.66

-0.48 (-1.77%)

, SVU

Supervalu

$32.47

-0.005 (-0.02%)

10:54
10/15/18
10/15
10:54
10/15/18
10:54
Recommendations
United Natural Foods, Supervalu analyst commentary  »

RBC says United Natural…

UNFI

United Natural Foods

$26.66

-0.48 (-1.77%)

SVU

Supervalu

$32.47

-0.005 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

NUGT

Direxion Gold Miners Bull

$16.72

1.32 (8.57%)

10:51
10/15/18
10/15
10:51
10/15/18
10:51
Technical Analysis
Technical Take: Direxion Gold Miners Bull has bullish price pattern »

There is an active…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.